ViiV registers two HIV studies: DDI trial for VH4011499 and NIAID-led PALACE trialNov 16Weekly roundup, 2 itemscabotegravirGilead Sciences
FDA accepts Palvella's NDA for QTORIN rapamycin, grants priority reviewOct 28Regulatory milestonePieris Pharmaceuticals, Inc.
Palvella submits first NDA module for QTORIN rapamycin, dosing begins in angiokeratoma trialAug 4Quarterly updatePieris Pharmaceuticals, Inc.